BioCryst Pharmaceuticals, Inc. has been awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services for the continued development of BCX4430 as a potential treatment for diseases caused by RNA pathogens, including filoviruses. This contract includes a base contract of $12.1 million to support BCX4430 drug manufacturing, as well as $22.9 million in additional development options that can be exercised by the Gov...